Table 2.
Low RAD51 score (HR deficient) |
Others (HR Competent) |
p value | |
---|---|---|---|
| |||
n | 15 | 42 | |
Median RAD51 score | 2% | 49% | |
Median age | 47 | 48 | 0.42+ |
Pathology | |||
IDC | 14 | 31 | 0.42 |
ILC | 1 | 8 | |
Medain tumour size (mm) | 60 | 50 | 0.09+ |
Histological grade | |||
2 | 3 | 22 | 0.031 |
3 | 12 | 17 | |
Axillary node positive | 36% (4/11) | 62% (21/34) | 0.17 |
ER positive | 43% (6/14) | 88% (29/33) | 0.003 |
HER2 positive | 21% (3/14) | 22% (6/27) | 1 |
Tumour subtype | |||
ER positive/HER2 negative | 4 | 24 | 0.0043 * |
HER2 positive | 3 | 6 | |
Triple negative | 8 | 4 | |
Median geminin 24 hr biopsy | 29.3% | 14.8% | <0.0001 + |
Median Ki67 | |||
Baseline | 44.2% | 21.3% | 0.005 + |
24 hr biopsy | 29.7% | 15.4% | 0.0012 + |
Clinical response | |||
CR | 3 | 7 | 0.2* |
PR | 11 | 24 | |
SD | 0 | 7 | |
PD | 0 | 3 | |
Pathological response | |||
Complete | 4 | 1 | 0.011 |
Not complete | 8 | 35 |
IDC- Invasive ductal carcinoma; ILC – Invasive lobular carcinoma. Statistical analysis was with Fisher's exact test, unless indicated + Mann-Whitney U Test or * Chi Squared test. Clinical response; CR – complete response; PR – partial response; SD – stable disease; PD – progressive disease. Pathological response data was not available on 9 cases as discussed in Supplementary figure 1.
Mann-Whitney U Test
Chi Squared test